Table 2.
Rank of efficacy of included treatments
| Treatment methods | BMD of lumbar vertebra | BMD of femoral neck | VAS | |||
|---|---|---|---|---|---|---|
| SUCRA value | Rank | SUCRA value | Rank | SUCRA value | Rank | |
| Jintiange capsule | 65.30% | 3 | 48.60% | 5 | — | — |
| Jintiange + physiotherapy + calcium | — | — | — | — | — | — |
| Jintiange + calcitonin | 53.40% | 5 | — | — | — | — |
| Jintiange + calcium | 29.10% | 9 | 40.10% | 8 | 83.4% | 1 |
| Jintiange + Estrogen | — | — | 56.00% | 4 | — | — |
| Jintiange + atorvastatin | 89.80% | 1 | 71.60% | 3 | — | — |
| Jintiange + BP + calcium | 53.60% | 4 | 41.70% | 7 | 62.8% | 2 |
| Jintiange + BP | 78.10% | 2 | 88.20% | 1 | 59.4% | 3 |
| physiotherapy + calcium | — | — | — | — | — | — |
| calcitonin | 41.30% | 6 | — | — | — | — |
| calcium +/VD | 11.70% | 10 | 11.00% | 10 | 18.8% | 6 |
| Estrogen | — | — | 44.10% | 6 | — | — |
| BP + calcium | 36.40% | 8 | 26.30% | 9 | 41.1% | 4 |
| BP | 41.20% | 7 | 72.60% | 2 | 34.6% | 5 |
BP, bisphosphonate; SUCRA, surface under the cumulative ranking; —, no report. For BMD (bone mineral density), the rank is upper when the value is higher; For VAS, the rank is upper when VAS is lower.